Recro Announces Executive Changes David Enloe Named President and Chief Executive Officer
December 16, 2020 07:00 ET | Source: Recro Pharma, Inc. Recro Pharma, Inc. Malvern, Pennsylvania, UNITED STATES
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today.
Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDMO businesses. Most recentl
Published: Dec 16, 2020
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today.
Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDMO businesses. Most recently, he served as President and Chief Executive Officer of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO. Under Mr. Enloe’s leadership, Aji Bio-Pharma’s revenues have increased over 50% in a four-year period and he led the